NCI: An inhibitor of one or more as of yet undisclosed bromodomain (BRD)-containing protein(s), with potential antineoplastic activity. Upon administration, the bromodomain inhibitor ABBV-075 binds to the acetyl-lysine binding site in the BRD of certain BRD-containing protein(s), thereby preventing the interaction between those proteins and acetylated histones. This disrupts chromatin remodeling, prevents the expression of certain growth-promoting genes, and leads to an inhibition of cell growth in susceptible tumors.
|Cas Registry Number||1445993-26-9|
|New Molecular Entity||Yes|
|Mechanism Of Action||Bromodomain and extraterminal domain protein inhibitor|
|Who Atc Codes||L01 (Antineoplastic Agents)|
|Ephmra Codes||L1 (Antineoplastics)|
|Indication||Advanced Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Acute Myeloid Leukemia, Multiple Myeloma|